Nu.Q vet cancer test now available through IDEXX’s reference laboratory network
Volition follows through on global supply agreement announced in October 2022
Volition, a multinational epigenetics company, announced today the availability of its Nu.Q Vet Cancer Test through the IDEXX reference laboratory network in the US.1
Tom Butera, DVM, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC, said: “IDEXX is a global leader in pet healthcare innovation and well-positioned to roll out the IDEXX Nu.Q Canine Cancer Screen worldwide. It is a simple, cost effective, easy to use blood test for screening older or ‘at risk’ dogs. Our Nucleosomics technology is easy to incorporate into annual wellness visits to support veterinarians in their clinical decision-making, enable earlier detection and treatment of cancer and improve the health and wellbeing of pets and pet owners."
Results from a clinical study at Texas A&M University, peer-reviewed and published in August 2022, showed that Volition’s Nu.Q Vet Cancer Test detected 76% of systemic cancers (including lymphoma, hemangiosarcoma, and histiocytic sarcoma) at 97% specificity versus control.2
“IDEXX’s launch of the Nu.Q Canine Cancer Screen in the US this week, under our previously announced supply agreement, ultimately provides worldwide customer reach through its global reference laboratory network as we continue to commercialize our transformational Nu.Q technology within the companion animal healthcare sector and capitalize on the significant opportunities available,” said Butera.
The Veterinary Cancer Society estimates that 1 in 4 dogs will develop cancer at some point, and almost 50% of dogs over the age of 10 will develop cancer.3 Approximately 6 million new cancer diagnoses are made in dogs in the US each year.4
- Volition announces expansion of availability of the Nu.Q® Vet Cancer Test through IDEXX’s Reference Laboratory Network. News Release. VolitionRx Limited. January 12, 2023.
- Wilson-Robles HM, Bygott T, Kelly TK, et al. Evaluation of plasma nucleosome concentrations in dogs with a variety of common cancers and in healthy dogs. BMC Vet Res. 2022;18(1):329. Published 2022 Aug 31. doi:10.1186/s12917-022-03429-8
- Frequently asked questions. Veterinary Cancer Society. Accessed January 12, 2023. http://vetcancersociety.org/pet-owners/faqs
- What is comparative oncology? National Cancer Institute Center for Research. Accessed January 12, 2023. https://ccr.cancer.gov/Comparative-Oncology-Program/pet-owners/what-is-comp-onc